



Clinical biomarkers

- Multidisciplinary testing platforms, including pathology, flow-cytometry and molecular biology technologies
- Enabling support to detect, develop, and validate biomarkers of cancer
- Essential guidance for early clinical development of candidate drugs

Platform and facility



Workflow and turnaround time



- Development, validation and optimization of new biomarker assay/panel : 2-3 months for pathology, 3-4 months for flow cytometry
- Clinical sample testing: 2-5 business days





Contact us

Technical: OIU-BD-Translation@wuxiapptec.com BD USA: declan.ryan@wuxiapptec.com BD EU/UK/Israel: dave_madge@wuxiapptec.com BD China: xu_longji@wuxiapptec.com BD Japan: fumio_itoh@wuxiapptec.com BD Korea: sycho@wuxiapptec.com



Application in clinical trials



Validated mIF panels for TME analysis



Establishing various tissue staining and whole slide image(WSI) analysis HE/IHC/multiplex IF/RNAscope/FISH/ISH+IHC, with direct labeling and TSA multiplex IF staining technology Quantitative pathology to interrogate protein/RNA expression in cancer, HALO vs InForm

digital pathological analysis

Invested World-class scanners–multispectral imaging, Single Cell Resolution HALO-LINK for DATA and whole scanned Image sharing

Application of NanoString technology - mechanism of action



Application of clinical-related flow cytometry - peripheral blood analysis in a single panel



- Multi-omics analysis utilizing multidisciplinary biomarker testing platforms to support the advancement of biomarkers in clinical trials for cancermmunotherapy
- Board-certified pathologists and immunologists with extensive knowledge and experience in oncology and immunology
- Well-trained and qualified technicians and skilled project managers to ensure proficient testing services
- Well-established management system to guarantee the high standards of accuracy and reliability
- CAP-accreditation and the compliance with GCP regulations for clinical trials